Viemed Healthcare Inc. Common Shares (VMD)

FairStock Score: 70/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Viemed is a home respiratory care and medical equipment business serving patients with chronic conditions such as COPD. The latest filing shows fiscal Q2 2026, the quarter ended 2026-06-30, revenue of $78.1 million, up from $63.1 million in fiscal Q2 2025, but net income slipped to $2.8 million from $3.2 million, and diluted EPS fell to $0.07 from $0.08. For fiscal 2025, the year ended 2025-12-31, revenue was $270.3 million and net income $14.9 million, or $0.37 per diluted share, versus $224.3 million and $11.3 million, or $0.28, in fiscal 2024. So the top line is moving, but the latest profit trend is not. FairStock computes a P/E of 26.69, P/B of 2.54, FCF yield of 8.0%, and EV/EBITDA of 6.84 at the 2026-10-13 close of $9.61. The balance sheet looks sturdy: debt-to-equity is 0.08, Piotroski is 8/9, Altman Z is 5.01, and TTM free cash flow is $29.2 million. Yet the Graham Number is only $5.53, leaving a margin of safety of -73.78%, and the computed Lynch category is SLOW GROWER - Shrinking, with profit down 13.9% a year over five years while revenue grew 15.5%. ROE of 10.45% and ROCE of 8.21% are respectable but not extraordinary. I see a decent, cash-generating business with low leverage, but the price already assumes better profit conversion than recent quarters show. Without a wider discount to intrinsic value, I would want clearer evidence that margins and earnings are inflecting upward.

In plain English: Viemed provides breathing equipment and home care services for patients with chronic lung conditions such as COPD. Sales are growing and the company has little debt and good cash flow, but the latest quarter's profit fell and margins are thin. At $9.61, the price looks expensive compared with the company's earnings and accounting value, so it is not an obvious bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer